Bone Biologics Corp — Director's Dealing 2025

Jun 6, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Bone Biologics Corp (BBLG)
CIK: 0001419554
Period of Report: 2025-06-04

Reporting Person: Gagnon Robert E. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-04	Non-Employee Stock Option	$0.88	A	62894	Acquired	2035-06-04	Common Stock (62894)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Employee Stock Option	$1.73	2034-09-17	Common Stock (30713)	30713	Direct
Non-Employee Stock Option	$4.68	2034-01-08	Common Stock (9)	9	Direct
Non-Employee Stock Option	$4.68	2034-01-08	Common Stock (8006)	8006	Direct

Footnotes

F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.

F2: This option was granted on 9/17/2024 and vests in four equal quarterly installments.

F3: This option is fully exercisable as of the date of this report.